Akero Therapeutics
The Director, Clinical Development will lead the execution of the Phase 3 program for efruxifermin (EFX), overseeing trial execution, medical monitoring, data analysis, and regulatory reporting. Reporting to the VP Clinical Development, the role serves as an internal and external medical expert, collaborating with cross‑functional teams and external stakeholders to ensure successful trial outcomes.
Headquarters
South San Francisco, California, United States
Company Size
11-50 employees
Founded
2017
Akero Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformational therapies for metabolic dysfunction‑associated steatohepatitis (MASH) and related metabolic diseases. Their lead investigational candidate, efruxifermin (EFX), is an engineered FGF21‑based therapy designed to improve metabolic health and reduce liver disease in people with MASH. Akero advances programs through clinical development with the goal of addressing underlying metabolic drivers of liver disease and improving long‑term patient outcomes.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Akero Therapeutics.
13% above the average for this role
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
Oct 14, 2025
Director/Senior Director, Clinical Development
Lexeo Therapeutics
Clinical Development Scientist
Azurity Pharmaceuticals
Medical Director, Clinical Development
Regeneron Pharmaceuticals
Associate Medical Director, Clinical Science, GI2 TAU
Takeda Pharmaceutical Company Limited
Director, Clinical Development AID
CRISPR Therapeutics
Clinical Trial Lead
IQVIA